N'-amino-4-methylpiperazine-1-carboximidamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N'-amino-4-methylpiperazine-1-carboximidamide
• 化学式: C₆H₁₅N₅
• 分子量: 157.22
• InChiKey: DKNMXBGUOFVDNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES<br/>[FR] COMPOSÉ APPROPRIÉ POUR LE TRAITEMENT DE SYNUCLÉOPATHIES
  申请人：NEUROPORE THERAPIES INC

  公开号：WO2011084642A1

  公开（公告）日：2011-07-14

  The present invention relates to a compound of formula (I): Wherein R1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt. I

  本发明涉及一种化合物，其化学式为（I）：其中R1是取代或未取代的芳香杂环或同环基，或取代或未取代的脂环杂环基；R2是具有1至18个碳原子的烷基基团或取代或未取代的环烷基或芳基；R3是取代或未取代的芳香杂环或同环基，或取代或未取代的脂环杂环基；L是单键，具有1至6个碳原子的烷基基团，NHCO，O，S，NHCONH或NHCOO；X、Y和Z分别为0、N、NH、S或CH；W是单键或具有1至6个碳原子的烷基基团；或其药学上可接受的盐或所述化合物或盐的药学上可接受的溶剂。
• Quinazoline analogs as receptor Tyrosine Kinase inhibitors
  申请人：Wallace Eli

  公开号：US20080194558A1

  公开（公告）日：2008-08-14

  This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R 3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  该发明涉及公式I的喹唑啉类似物：其中A基团与双环环上的5、6、7或8位置中的至少一个碳原子结合，并且环被多达三个独立的R3基团取代。该发明还包括使用这些化合物作为类型I受体酪氨酸激酶抑制剂以及用于治疗癌症等增殖过度性疾病的方法。
• QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Wallace Eli

  公开号：US20090270621A1

  公开（公告）日：2009-10-29

  This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R 3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明涉及公式I的喹唑啉类似物：其中A基团连接到双环环上的5、6、7或8位置之一的碳上，环被多达三个独立的R3基团取代。本发明还包括将这些化合物用作I型受体酪氨酸激酶抑制剂并用于治疗癌症等增生性疾病的方法。
• Compound Suitable for the Treatment of Synucleopathies
  申请人：Masliah Eliezer

  公开号：US20130035342A1

  公开（公告）日：2013-02-07

  The present invention relates to a compound of formula (I): Wherein R 1 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; R 2 is an alkyl group with 1 to 18 carbon atoms or a substituted or unsubstituted cycloalkyl or aryl group; R 3 is a substituted or unsubstituted aromatic hetero- or homocyclic or a substituted or unsubstituted alicyclic hetero- or homocyclic group; L is a single bond, an alkyl group having 1 to 6 carbon atoms, NHCO, O, S, NHCONH or NHCOO; X, Y and Z are independently 0, N, NH, S or CH; W is a single bond or an alkyl group having from 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of said compound or salt.

  本发明涉及一种式为（I）的化合物：其中，R1是取代或未取代的芳香杂环或同环或取代或未取代的脂环杂环或同环基团；R2是1至18个碳原子的烷基基团或取代或未取代的环烷基或芳基基团；R3是取代或未取代的芳香杂环或同环或取代或未取代的脂环杂环或同环基团；L是单键、具有1至6个碳原子的烷基基团、NHCO、O、S、NHCONH或NHCOO；X、Y和Z独立地为0、N、NH、S或CH；W是单键或具有1至6个碳原子的烷基基团；或其药学上可接受的盐或该化合物或盐的药学上可接受的溶剂化物。
• COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES
  申请人：Neuropore Therapies, Inc.

  公开号：US20140364610A1

  公开（公告）日：2014-12-11

  The present invention relates to certain heteroaromatic compounds of Formula (Ia), or pharmaceutically acceptable salts thereof, and uses of such compounds in the treatment of synucleopathies.

  本发明涉及公式（Ia）的某些杂环芳香化合物，或其药学上可接受的盐，并且涉及在治疗突触核病中使用此类化合物的用途。